Evidence map›Paper›PMID 37708230›Full record

Observational studyPloS one2023

From past to present: Exploring COVID-19 in Qatar's hemodialysis population across Omicron dominant and pre-Omicron periods.

Abdullah Hamad, Musab Elgaali, Tarek Ghonimi, Mostafa Elshirbeny, Mohamed Ali, Rania Ibrahim, Muftah Othman, Essa Abuhelaiqa, Hany Ezzat, Karima Boubaker and 2 more

Abstract readObservational Study
In one paragraph

Observational study in PloS one, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Abdullah HamadDivision of Nephrology, Department of Medicine, Hamad Medical Corporation, Doha, Qatar.ORCID 0000-0003-4677-7686
Musab ElgaaliDivision of Nephrology, Department of Medicine, Hamad Medical Corporation, Doha, Qatar.
Tarek GhonimiDivision of Nephrology, Department of Medicine, Hamad Medical Corporation, Doha, Qatar.
Mostafa ElshirbenyDivision of Nephrology, Department of Medicine, Hamad Medical Corporation, Doha, Qatar.
Mohamed AliDivision of Nephrology, Department of Medicine, Hamad Medical Corporation, Doha, Qatar.
Rania IbrahimDivision of Nephrology, Department of Medicine, Hamad Medical Corporation, Doha, Qatar.
Muftah OthmanDivision of Nephrology, Department of Medicine, Hamad Medical Corporation, Doha, Qatar.
Essa AbuhelaiqaDivision of Nephrology, Department of Medicine, Hamad Medical Corporation, Doha, Qatar.
Hany EzzatDivision of Nephrology, Department of Medicine, Hamad Medical Corporation, Doha, Qatar.
Karima BoubakerDivision of Nephrology, Department of Medicine, Hamad Medical Corporation, Doha, Qatar.
Mohamad AlkadiDivision of Nephrology, Department of Medicine, Hamad Medical Corporation, Doha, Qatar.
Hassan Al-MalkiDivision of Nephrology, Department of Medicine, Hamad Medical Corporation, Doha, Qatar.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

COVID-19 carries a high risk of morbidity and mortality in dialysis patients. Multiple SARS-CoV-2 variants have been identified since the start of the COVID-19 pandemic. The current study aimed to compare the incidence and outcomes of the COVID-19 Omicron dominant period versus other pre-Omicron period in hemodialysis patients. In this observational, analytical, retrospective, nationwide study, we reviewed adult chronic hemodialysis patients between March 1, 2020, and January 31, 2022. Four hundred twenty-one patients had COVID-19 during the study period. The incidence of COVID-19 due to the Omicron dominant period was significantly higher than other pre-Omicron period (30.3% vs. 18.7%, P<0.001). In contrast, the admission rate to ICU was significantly lower in the Omicron dominant period than in the pre-Omicron period (2.8% vs. 25%, P<0001) but with no significant difference in ICU length of stay. The mortality rate was lower in the Omicron dominant period compared to the pre-Omicron period (2.4% vs. 15.5%, P<0.001). Using multivariate analysis, older age [OR 1.093 (95% CI 1.044-1.145); P<0.0001] and need for mechanical ventilation [OR 70.4 (95% CI 20.39-243.1); P<0.0001] were identified as two independent risk factors for death in hemodialysis patients with COVID-19. In Conclusion, the COVID-19 Omicron variant had a higher incidence and lower morbidity and mortality than pre-Omicron period in our hemodialysis population.

Indexed as

COVID-19AdultHumansPandemicsQatarRenal DialysisRetrospective StudiesSARS-CoV-2

Identifiers

PMID37708230
PMCPMC10501587

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.